Zoledronic Acid As a Therapeutic For Dry Age-Related Macular Degeneration and Stargardt Disease

Tech ID: 32906 / UC Case 2022-156-0

Technology Description

The invention is a therapeutic intended to prevent the onset and progression of age-related macular degeneration (MD) as well as Stargardt disease-related vision loss. 

 UCSF/University of Wisconsin researchers have identified that abnormal activation of acid sphingomyelinase (ASM) in the retinal pigment epithelium (RPE) serves as a pathological trigger in dry age-related MD and Stargardt’s disease. Activation of ASM results in increased ceramide, which makes the RPE (the tissue that is responsible for nourishment and support of light-sensing photoreceptors) susceptible to damage.  The RPE is the primary site of damage for both Stargardt inherited and age-related MD. 

Advantages

  • Potential preventative treatment for age-related MD and Stargardt disease
    • ~ 35 million people worldwide suffer from age-related MD
    • Stargardt disease affects ~1 in 8,000 children
  • Treatment with bisphosphonate zoledronic acid (the only known structural inhibitor of ASM) can prevent ceramide accumulation and preserve the RPE
    • In vivo efficacy in mouse models of MD is observed with a 2,000-fold lower dose than that used for functional ASM inhibitors and 15-fold lower dose of ZA than that currently used to treat osteoporosis.
    • Currently, there are no approved therapies for dry age-related MD (which is characterized by focal loss of the RPE) or Stargardt disease

 

Application

  • Therapy to prevent
    • age-related MD onset or progression
    • vision loss due to Stargardt disease
  • Potential therapy for any condition associated with increased ceramide. 
    • Excess ceramide has been implicated in many diseases, including Alzheimer’s and Parkinson’s disease.

Stage of Development

Target validation and proof of concept translational studies. 

Treatment with an ultra-low dose of Zoledronic acid has been shown to prevent ceramide accumulation while preserving RPE health and function in cell-based models of AMD and in vivo in the Abca4-/- mouse model of Stargardt inherited MD

Looking for Partners

To further develop the technology

Data Availability

Under CDA

Patent Status

Patent Pending

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As